GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Mesothelin-targeted immunotoxins in Pancreatic Cancer

$476,998
Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA

Interstitial Fluid Flow Regulates Glioma Cell Invasion

$476,966
Jennifer M Munson · Virginia Polytechnic Inst And St Univ · R37 · FY2021 · CA

Metastatic Clonal Heterogeneity and its Impact on Melanoma Therapeutic Resistance

$476,960
Willy Hugo · University Of California Los Angeles · R01 · FY2020 · CA

GENETIC ALTERATION IN EPITHELIAL AND STROMAL COMPARTMENT OF BREAST ADENOCARCINOMA

$476,934
Charis Eng · Ohio State University · P01 · FY2007 · CA

Definition of the Microenvironment in Breast Cancer

$476,933
Mina J Bissell · University Of Calif-Lawrenc Berkeley Lab · R01 · FY2019 · CA

Boosting Antitumor Immunity by Blocking Both Tumor and Adipose DDR1

$476,885
Rong Li · George Washington University · R01 · FY2020 · CA

Engineered hybrid aging model for disease progression

$476,827
Pinar Zorlutuna · University Of Notre Dame · R01 · FY2023 · CA

Integrin-mediated mechanisms of prostate cancer progression

$476,796
Lucia R Languino · Thomas Jefferson University · R01 · FY2020 · CA

Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors

$476,752
Wei R. Chen · University Of Oklahoma · R01 · FY2023 · CA

Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy

$476,736
Xinna Zhang · Indiana University Indianapolis · R01 · FY2024 · CA

Regulation of metastatic progression by an endothelial-derived factor

$476,712
Sohail F. Tavazoie · Rockefeller University · R01 · FY2021 · CA

Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas

$476,622
Elias Sayour · University Of Florida · R37 · FY2022 · CA

IGF::OT::IGF ANTI FUSOBACTERIUM NUCLEATUM VACCINE FOR COLORECTAL CANCER IMMUNOPREVENTION

$476,619
Steven Monroe Lipkin · Weill Medical Coll Of Cornell Univ · N01 · FY2017 · CA

Nanoparticles-mediated combination therapy for breast cancer

$476,617
Song Li · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA

Exploiting oxidative stress response in uveal melanoma liver metastases

$476,587
Edward Hartsough · Drexel University · R01 · FY2024 · CA

A novel role of IGFBP7 in the microenvironment of hepatocellular carcinoma

$476,580
Devanand Sarkar · Virginia Commonwealth University · R01 · FY2022 · CA

A novel role of IGFBP7 in the microenvironment of hepatocellular carcinoma

$476,580
Devanand Sarkar · Virginia Commonwealth University · R01 · FY2023 · CA

Understanding the induction of T cell dysfunction in the context of lung cancer

$476,553
Stefani Spranger · Massachusetts Institute Of Technology · R37 · FY2023 · CA

Image Biomarker Development for TreatmentEfficacy of Prostate Cancer to the Bone

$476,542
Brian D. Ross · University Of Michigan At Ann Arbor · R01 · FY2012 · CA

The role of Interleukin 17RB signaling in colorectal cancer progression

$476,341
Sergei I Grivennikov · Cedars-Sinai Medical Center · R01 · FY2021 · CA

Mechanistic and therapeutic investigation of secondary metastatic seeding from breast cancer bone lesion

$476,224
Xiang Zhang · Baylor College Of Medicine · R01 · FY2022 · CA

Mechanistic and therapeutic investigation of secondary metastatic seeding from breast cancer bone lesion

$476,224
Xiang Zhang · Baylor College Of Medicine · R01 · FY2023 · CA

Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer

$476,037
Katarzyna Anna Rejniak · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA

Role of EGFR in signaling by receptors of intracellular nucleic acids

$476,003
Ganes C. Sen · Cleveland Clinic Lerner Com-Cwru · P01 · FY2016 · CA

Project 3: Phase-2 Trial of Oncolytic Poliovirus (PVSRIPO) combined with CCNU (lomustine) against Recurrent Glioblastoma

$475,986
Darell D Bigner · Duke University · P01 · FY2019 · CA